N/A N=120 Multicenter Study Comparing OsseoSpeed TX With OsseoSpeed EV.
Partial Edentulism in the Maxilla or in the Mandible
Primary: Marginal Bone Level Change After 1 Year in Use. — 0.27; 0.14 Millimeter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=314 TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Diagnostic Test Data for Disease Using Tear Osmolarity Threshold > 308 mOsm/L — 177; 14; 47; 61 participants
Phase 1 N=39 Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)
Advanced Non Small Cell Lung Cancer · Advanced (Inoperable) Non Small Cell Lung Cancer
Primary: Cmax of AZD9291 — 242.5; 201.7 nM
Early Phase 1 N=18 Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
Psychotic Disorders
Primary: Brief Psychiatric Rating Scale (Overall & Gorham, 1962) — -8.0; -11.6 percentage of total possible change
Phase 1 N=48 Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.
Healthy
Primary: Maximum Mean Placebo-corrected QTcN Change From Baseline Between 1 to 24 Hours on Day 1 for the Combination Therapy — -0.47; -8.37 ms
Phase 3 N=157 Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty
Primary Generalized (Osteo)Arthritis · Post-traumatic Arthrosis of Other Joints, Upper Arm
Primary: Device Success Rate — 134 participants
Phase 3 N=1,443 Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
HIV · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 95.6; 92.9; 97.2; 93.1 percentage of participants — p=0.051
Phase 3 N=60 Sensoril(Ashwaganhda)for Bipolar Disorder
Bipolar I Disorder · Bipolar II Disorder · Bipolar Disorder NOS
Primary: Change From Baseline in Digit-Span Score at 8 Weeks — 0.73; 0.17 units on a scale
Phase 3 N=441 Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
Complicated Intra-abdominal Infection
Primary: The Proportion of Patients With Clinical Cure at the Test of Cure (TOC) Visit in the Clinically Evaluable (CE) Analysis Set. — 166; 173; 11; 11 Number of patients…
Phase 4 N=30 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
Coronary Artery Disease
Primary: Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo — 8.8; 10.7 mL/min — p=0.756
Phase 2 N=245 Prevention of Post Sexual Assault Stress
Drug Use · Drug Abuse · Posttraumatic Stress Disorder
Primary: Drug Abuse Screening Test (DAST-10) — 1.97; 2.03; 1.18 units on a scale — p=.24
Phase 3 N=2,423 Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Mean Change From Baseline (BL) in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1, on Treatment Day 84 — 0.116; 0.082 Liter — p=0.001
Phase 3 N=399 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
Epilepsy
Primary: Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period — 1.75; 1.34; 1.49; 1.26 Seizure Frequency per Week — p==0.261
N/A N=327,293 Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine
Pertussis
Primary: Twenty One Pre-specified Outcomes of Interest as Obtained From International Coding of Diseases (ICD-9) Codes Captured After Adacel Vaccination in Clinical Database — 0…
Phase 2 N=20 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Mixed Mullerian Tumors of the Uterus
Primary: Chemotherapy Completion Rate — 100 percentage of participants